Abstract
In 1999, a meta-analysis on the efficacy and tolerability of α1-adrenoceptor (α1-AR) antagonists in treating lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) was published.1 Since then, new data, including those from studies with new formulations (ie, alfuzosin prolonged release [XL] and doxazosin gastrointestinal therapeutic system [GITS]) have become available. Therefore, we aimed in the present report to update the analysis published in 1999 to assess whether these α1-AR antagonists can be distinguished with regard to efficacy and/or tolerability.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
